BioStem Technologies Schedules Q1 2026 Financial Results Call for May 14

BioStem Technologies, Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced today that it will release its first quarter 2026 financial results after the market close on Thursday, May 14, 2026. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide a business update.

The webcast will feature an overview of the quarter from BioStem Technologies management. Investors and interested parties can register for the event here. The conference call can be accessed by dialing (800) 715-9871 (North America toll-free) or +1 (646) 307-1963 (international toll) using conference ID 9695874.

BioStem Technologies focuses on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages proprietary processing technologies, including BioRetain®, CryoTek®, and SteriTek®, designed to preserve the natural properties of these tissues for clinical use. Its allografts are used by clinicians across a wide range of medical specialties. The company’s quality management system has been reviewed and accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP).

The announcement of the financial results call comes as BioStem continues to expand its portfolio of products and clinical research initiatives. With a national commercial footprint, the company is committed to advancing innovation in regenerative medicine. Its portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion product lines.

For more information, interested parties can visit the company’s newsroom at https://tinyurl.com/bsemnewsroom. The company also maintains a presence on social media platforms X and LinkedIn, where updates are regularly posted.

The first quarter financial results and subsequent call are expected to provide insights into the company’s performance and strategic direction. Analysts and investors will be watching for updates on revenue growth, product adoption, and any developments in clinical research. As a publicly traded entity under the ticker BSEM, BioStem’s financial health and operational milestones are of interest to the regenerative medicine sector and broader investment community.

This news story relied on content distributed by PRISM Mediawire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is BioStem Technologies Schedules Q1 2026 Financial Results Call for May 14.

The post BioStem Technologies Schedules Q1 2026 Financial Results Call for May 14 appeared first on citybuzz.